Could a malaria drug help lung cancer patients stay ahead of resistance?

NCT ID NCT00977470

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 24 times

Summary

This study tested whether adding hydroxychloroquine (a malaria drug) to the standard targeted therapy erlotinib could delay or prevent drug resistance in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 76 participants received either erlotinib alone or erlotinib plus hydroxychloroquine. The goal was to see if the combination kept the cancer from growing longer than erlotinib alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Stanford Cancer Institute

Stanford, California, 94305, United States
University of Maryland

Baltimore, Maryland, 21201, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER